NCT04526223

Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Allogeneic HCT Outcomes in MF Patients Exposure to Ruxolitinib During Transplantation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: xuna · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation 1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor 5. received Rux at +6d in ASCT and continued to +60d

Conditions

• Time of Hematopoietic Reconstruction

Interventions

Type	Name	Description
OTHER	comprehensive treatment regimen	1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF) 2. With at least two month Ruxolitinib treatment prior to transplantation 3. DAC+BF as myeloablative conditioning regimen 4. received Rux at +5d in ASCT and continued to +60d

Timeline

• Start date: 2017-04-20
• Primary completion: 2022-12-20
• Completion: 2022-12-31
• First posted: 2020-08-25
• Last updated: 2022-04-15

Locations

1 site across 1 country: China